Q-omics provides the consensus-scored RPL27AP5 profile across patient tissues and cancer cell-line models. RPL27AP5 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RPL27AP5 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RPL27AP5 RNA expression shows 10,876 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KICH, COAD, and DLBC as cancer lineages where RPL27AP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL27AP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL27AP5 survival associations across molecular data types. RPL27AP5 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL27AP5 RNA expression–survival associations across cancer types. High RPL27AP5 expression shows unfavorable associations in KICH, ACC and KIRC, but favorable associations in THCA, LUSC and READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for RPL27AP5 RNA expression.
This table summarizes RPL27AP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL27AP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL27AP5 shows lower tumor expression in HNSC and higher tumor expression in COAD, KIRC, LIHC and LUAD. The COAD box plot shows higher RPL27AP5 RNA expression in tumor versus normal tissue (log2 FC = +0.895, t-test p < 0.001).
This table shows molecular features associated with RPL27AP5 in patient tissues and cancer cell lines. In patient samples, RPL27AP5 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
